Which one of the following is NOT part of the approach to Phase H – Architecture Change
Management?

Scenario
Please read this scenario prior to answering the question
You are serving as the Lead Architect for an enterprise architecture project team within a leading
multinational pharmaceutical and medical devices manufacturer. Its brands include numerous
household names for medications and first aid supplies.
The company has a long history of innovating new treatments for many common illnesses and
diseases. Prior to launching a new treatment, the company has to demonstrate its effectiveness and
safety in a set of clinical trials that satisfy the regulatory requirements of the countries in the target
markets. All clinical trials are undertaken by its research laboratories, which employ over 10,000
people at separate facilities in the United Kingdom, United States, Sweden, France, Canada, India,
China and Japan. In addition to internal research and development activities the company is also
involved in publicly funded collaborative research projects, with other industrial and academic
partners.
The Enterprise Architecture group within the company has been engaged in an architecture
development project to create a secure networked collaboration system that will allow researchers
at its product development laboratories worldwide to share information about their clinical trials.
This system will also connect with external partners.
The Enterprise Architecture group is a mature organization. They use the TOGAF 9 ADM with
extensions required to support current good manufacturing practices and good laboratory practices
in their target markets. Due to the highly sensitive nature of the information that is managed, special
care was taken to ensure that each architecture domain included an examination of the security and
privacy issues that are relevant.
The Executive Vice President for Clinical Research is the sponsor of the Enterprise Architecture
activity. She has stated that the changes to the enterprise architecture for the new system will need
to be rolled out in stages on a regional basis that minimizes disruptions to ongoing clinical trials.
Refer to the Scenario
You have been asked to recommend the approach to identify the work packages that will be
included in the Transition Architecture(s).
Based on TOGAF, which of the following is the best answer?

When determining the requirements for enterprise architecture work in the Preliminary
Phase, Which of the following is not a business imperative that should be considered?